Journal article
Growth inhibition of prostate cancer xenografts by halofuginone*†
Abstract
BACKGROUND: Halofuginone, an inhibitor of collagen type I synthesis, is an anti-angiogenic agent. Here we evaluated the efficacy of halofuginone to inhibit prostate cancer (PC) xenografts representing various phenotypes of the disease.
METHODS: An androgen-dependent (CWR22), an androgen-independent (PC3), and a neuroendocrine (WISH-PC2) PC xenograft were used. Halofuginone was given orally or injected intraperitoneally. Tumor size, collagen …
Authors
Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
Journal
The Prostate, Vol. 51, No. 2, pp. 73–83
Publisher
Wiley
Publication Date
May 2002
DOI
10.1002/pros.10059
ISSN
0270-4137
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdenocarcinomaAdministration, OralAndrogensAnimalsAntineoplastic AgentsApoptosisCollagen Type IDNA, NeoplasmDisease ProgressionDose-Response Relationship, DrugGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ HybridizationInjections, IntraperitonealMaleMiceMice, SCIDNecrosisNeovascularization, PathologicPhenotypePiperidinesProstatic NeoplasmsQuinazolinesQuinazolinones